Sult1a1 Antibody

What is SULT1A1 and what is its function in human tissues?

SULT1A1 (Cytosolic Sulfotransferase 1A1) is a key enzyme that catalyzes the sulfate conjugation of diverse compounds bearing hydroxyl or amine groups. It utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as a sulfonate donor to increase water solubility of compounds, facilitating their renal excretion . SULT1A1 exists as a homodimer and is widely expressed in multiple tissues including liver, lung, adrenal gland, brain, platelets, and skin .

The enzyme plays a dual role in human metabolism: it detoxifies many xenobiotics but can also bioactivate certain compounds, potentially creating mutagenic metabolites. This dual functionality makes SULT1A1 particularly interesting in cancer research, as it can transform some xenobiotics into cellular mutagens and carcinogens . The enzyme also mediates the sulfate conjugation of endogenous molecules such as steroid hormones and various xenobiotics including drugs like acetaminophen and minoxidil .

What types of SULT1A1 antibodies are available for research applications?

Researchers can access several types of SULT1A1 antibodies optimized for different experimental applications:

• Polyclonal antibodies: Such as rabbit polyclonal antibodies that recognize specific epitopes within the SULT1A1 protein. These typically offer broader epitope recognition but may have higher background .

• Monoclonal antibodies: These offer higher specificity for particular epitopes of SULT1A1. For instance, Clone #638708 is a monoclonal antibody raised against recombinant human Cytosolic Sulfotransferase 1A1/SULT1A1 spanning Glu2-Leu295 .

• Antigen affinity-purified antibodies: These undergo additional purification steps to enhance specificity, such as the Goat Anti-Human Cytosolic Sulfotransferase 1A1/SULT1A1 Antigen Affinity-purified Polyclonal Antibody .

Most commercially available antibodies are validated for applications including Western blotting, immunohistochemistry on paraffin-embedded tissues (IHC-P), and Simple Western assays .

How should I optimize Western blot protocols for SULT1A1 detection?

Optimizing Western blot protocols for SULT1A1 detection requires careful consideration of several parameters:

• Sample preparation: Liver tissue lysates provide strong positive controls for SULT1A1 detection, as demonstrated in multiple validation studies . HEK293 cell lysates can also be used as a cellular model .

• Protein loading: Typical protocols use 0.2-0.5 mg/mL of tissue lysate for optimal detection .

• Antibody dilution: Start with manufacturer recommendations, typically:

  • For polyclonal antibodies: 1:1000 dilution range

  • For monoclonal antibodies: 0.5-1 μg/mL concentration

• Detection conditions: SULT1A1 appears at approximately 35-38 kDa band size under reducing conditions . Use appropriate reducing agents and buffer systems - Immunoblot Buffer Group 1 or 8 has been validated in published protocols .

• Secondary antibody selection: Match to your primary antibody host species. For example, use HRP-conjugated Anti-Mouse IgG Secondary Antibody for mouse monoclonal primaries or HRP-conjugated Anti-Goat IgG Secondary Antibody for goat polyclonal primaries .

When troubleshooting, remember SULT1A1 exists as a homodimer in its native state, but under the denaturing conditions of standard Western blot it will appear as a monomeric band at 35-38 kDa .

What are the key considerations for immunohistochemical detection of SULT1A1?

Successful immunohistochemical detection of SULT1A1 requires attention to several critical factors:

• Tissue fixation and processing: Paraffin-embedded sections are typically used after formalin fixation .

• Antigen retrieval: Heat-induced epitope retrieval using basic antigen retrieval reagents is crucial for optimal staining. This step is essential as formalin fixation can mask epitopes .

• Antibody concentration: For IHC applications, higher concentrations are often needed compared to Western blot. Published protocols recommend 15 μg/mL of anti-SULT1A1 monoclonal antibody with overnight incubation at 4°C .

• Detection systems: HRP-DAB (horseradish peroxidase-diaminobenzidine) systems are commonly used, producing a brown chromogenic signal that can be counterstained with hematoxylin for contrast .

• Pattern interpretation: SULT1A1 staining in brain tissue appears as punctate patterns in neurons and glial cells . The staining pattern may vary by tissue type, reflecting the biological distribution of the enzyme.

For consistent results, include both positive controls (known SULT1A1-expressing tissues like liver) and negative controls (primary antibody omission or isotype controls) in each experiment.

How do SULT1A1 genetic polymorphisms affect enzyme function and disease associations?

SULT1A1 genetic polymorphisms significantly influence enzyme activity, substrate specificity, and disease associations:

• SULT1A1*2 polymorphism (Arg213His substitution):

  • Reduces catalytic activity and thermostability of the enzyme

  • Shows differential cancer risk associations based on cancer type and ethnicity:

    • Increases risk for upper aerodigestive tract (UADT) cancers (OR=1.62, 95% CI: 1.12, 2.34)

    • Decreases risk for genitourinary cancers (OR=0.73, 95% CI: 0.58, 0.92)

    • Shows ethnicity-dependent breast cancer risk:

      • Increases risk in Asian women (OR=1.91, 95% CI: 1.08, 3.40)

      • No significant risk association in Caucasian women (OR=0.92, 95% CI: 0.71, 1.18)

• Bioactivation of carcinogens:

  • SULT1A1 can activate N-hydroxyarylamines to form DNA adducts, potentially initiating mutagenesis

  • The variability in enzyme activity due to polymorphisms may explain differential cancer susceptibility

When investigating SULT1A1 polymorphisms in disease association studies, researchers should consider:

• Stratification by ethnicity and cancer type

• Potential interaction with environmental and dietary factors

• Use of appropriate statistical methods for meta-analysis when combining data across studies

The complex role of SULT1A1 in both detoxification and bioactivation pathways necessitates careful experimental design when studying its relationship to disease states.

What are the critical parameters for designing valid SULT1A1 enzyme activity assays?

Designing valid SULT1A1 enzyme activity assays requires careful consideration of the enzyme's complex mechanism, which includes allosteric regulation and partial substrate inhibition:

• PAPS concentration considerations:

  • SULT1A1 turnover and selectivity are highly responsive to PAPS concentrations

  • For comparing activities across substrates or tissues, use high (approximately 0.50 mM) PAPS concentrations to alleviate issues related to substrate size variations and active-site cap opening

  • For physiologically relevant assessments, match PAPS concentrations to those in the target tissue cytosol

• Substrate inhibition considerations:

  • SULT1A1 exhibits partial substrate inhibition with many substrates

  • Ensure that kinetic measurements cover a sufficiently broad substrate concentration range to capture both activation and inhibition phases

  • Avoid single-point activity measurements as they may fall in either the rising or falling phase of the activity curve

• Assay design recommendations:

  • Use initial-rate conditions to avoid product inhibition effects

  • Consider enzyme stabilization (e.g., inclusion of BSA or glycerol) as SULT1A1*2 variants have reduced thermostability

  • Include appropriate controls to account for chemical instability of PAPS

  • For tissue extracts, assess potential interference from endogenous inhibitors

Following these guidelines ensures that SULT1A1 activity measurements provide physiologically relevant and mechanistically sound data.

How does SULT1A1 deletion affect metabolic parameters in animal models?

Recent studies on Sult1a1 knockout (KO) mice have revealed intriguing metabolic phenotypes:

• Body weight and adipose tissue effects:

  • Sult1a1 KO mice show a tendency for lower body weight

  • Most striking finding is remodeling of white adipose tissue toward a brown phenotype

  • Subcutaneous adipose tissue from KO mice exhibited significantly increased leak respiration

  • Molecular changes include increased expression of UCP1 (uncoupling protein 1) and VDAC (voltage-dependent anion channel), an outer mitochondrial membrane protein

• Glucose homeostasis effects:

  • Sult1a1 deletion had minimal effects on glucose homeostasis under normal conditions

  • On high-fat diet, KO mice were less hyperinsulinemic, suggesting potential protection against insulin resistance

  • Reduced immune cell infiltration and fibrosis in adipose tissue of KO mice further supports potential long-term protection against insulin resistance

• Species differences:

  • Differences in adipose tissue browning capacity between anatomical sites may explain some disparities between human and mouse studies

  • Mice and humans may have opposing patterns of adipose tissue browning capability, with subcutaneous depots (iWAT) in mice having higher browning potential than visceral depots (eWAT)

These findings suggest SULT1A1 may play previously unrecognized roles in energy metabolism and adipose tissue function, opening new research directions beyond its established role in xenobiotic metabolism.

What are the optimal strategies for validating SULT1A1 antibody specificity?

Validating SULT1A1 antibody specificity is crucial for generating reliable research data. A comprehensive validation strategy should include:

• Positive and negative control tissues:

  • Positive controls: Human liver tissue consistently shows strong SULT1A1 expression

  • Alternative positive controls: HEK293 cells, platelets, and brain tissue

  • Negative controls: Tissues known to express minimal SULT1A1 or SULT1A1-knockout models where available

• Multiple detection methods:

  • Western blot: Should show a specific band at the expected molecular weight (35-38 kDa)

  • Immunohistochemistry: Should demonstrate the expected cellular and subcellular localization pattern

  • Peptide competition: Pre-incubation with the immunizing peptide should abolish specific signal

• Knockdown/knockout validation:

  • siRNA knockdown of SULT1A1 in cell lines

  • CRISPR-Cas9 knockout cell lines

  • Tissues from SULT1A1 knockout animals where available

• Cross-reactivity assessment:

  • Testing against related SULT family members to ensure specificity

  • Evaluating species cross-reactivity if using the antibody across different animal models

A well-validated antibody should demonstrate consistent results across multiple detection methods and show appropriate signal reduction in genetic knockdown/knockout models.

How should researchers address potential contradictions in SULT1A1 expression data across studies?

When facing contradictory SULT1A1 expression data across different studies, researchers should systematically evaluate several factors:

• Antibody characteristics:

  • Different antibodies target different epitopes and may have varying specificities

  • Polyclonal antibodies may detect multiple isoforms or related family members

  • Monoclonal antibodies may miss certain variants or polymorphic forms

• Tissue and sample preparation differences:

  • SULT1A1 expression can vary based on tissue fixation methods

  • Protein extraction protocols may differentially recover SULT1A1

  • Post-translational modifications may affect antibody recognition

• Genetic and environmental factors:

  • SULT1A1 polymorphisms affect expression levels and can vary across populations

  • Environmental factors, medication use, and hormonal status can modulate SULT1A1 expression

  • Disease states may alter normal expression patterns

• Resolution strategies:

  • Use multiple antibodies targeting different epitopes

  • Employ complementary techniques (e.g., mRNA quantification, activity assays)

  • Consider genetic background and environmental factors in experimental design

  • Clearly document and report all methodological details to facilitate cross-study comparison

When integrating contradictory results, a weight-of-evidence approach considering methodological rigor, sample size, and consistency with biochemical and functional data is recommended.

What are the recommended protocols for comparing SULT1A1 levels across different tissue types?

Comparing SULT1A1 levels across different tissue types requires standardized protocols to account for tissue-specific variables:

• Sample preparation considerations:

  • Standardize tissue collection and storage procedures

  • Use consistent protein extraction methods optimized for each tissue type

  • Consider tissue-specific matrix effects that may influence antibody binding

• Quantification approach:

  • Use quantitative Western blotting with recombinant SULT1A1 standards for calibration

  • Include internal loading controls appropriate for each tissue type

  • Consider absolute quantification methods like ELISA or mass spectrometry-based approaches

• Validation across methods:

  • Correlate protein detection with mRNA expression (qPCR)

  • Validate with enzyme activity assays to confirm functional expression

  • Use immunohistochemistry to determine cellular distribution within tissues

• Data normalization and comparison:

  • Normalize to total protein rather than single housekeeping proteins

  • Account for differences in cellular composition between tissues

  • Present data as both absolute values and relative to appropriate reference tissues

• Statistical analysis:

  • Use appropriate statistical tests for multiple tissue comparisons

  • Consider paired designs when comparing tissues from the same subjects

  • Report variability measures and sample sizes clearly

Following these guidelines will help ensure that observed differences in SULT1A1 levels between tissues reflect true biological variation rather than methodological artifacts.

How can SULT1A1 antibodies be used to investigate gut microbiota-host metabolic interactions?

Recent discoveries point to SULT1A1's role in gut microbiota-host metabolic interactions, opening new research applications for SULT1A1 antibodies:

• Metabolite conjugation:

  • SULT1A1 O-sulfonates 4-ethylphenol (4-EP), a dietary tyrosine-derived metabolite produced by gut bacteria

  • The resulting product, 4-EPS, can cross the blood-brain barrier and potentially affect oligodendrocyte maturation and myelination

  • SULT1A1 antibodies can help map the tissue distribution of this enzyme in relation to microbiome-derived metabolite processing

• Experimental approaches:

  • Immunohistochemical mapping of SULT1A1 expression along the intestinal tract

  • Co-localization studies with transporters involved in microbial metabolite uptake

  • Western blot analysis of SULT1A1 expression changes in response to microbiome alterations

  • Immunoprecipitation to identify protein-protein interactions relevant to microbiome metabolite processing

• Translational applications:

  • Investigating how antibiotic treatment affects SULT1A1 expression and activity

  • Studying the relationship between diet, microbiome composition, and SULT1A1-mediated metabolism

  • Exploring connections between microbiome-derived metabolites, SULT1A1 activity, and neurological function

This emerging research area connects SULT1A1's established role in xenobiotic metabolism with the growing field of microbiome research, potentially providing insights into microbiome-related disease mechanisms.

What are the recent advances in understanding SULT1A1's role in cancer risk assessment?

Recent advances have refined our understanding of SULT1A1's complex role in cancer risk assessment:

• Meta-analysis findings:

  • SULT1A1*2 polymorphism shows tissue-specific and ethnicity-dependent cancer risk associations

  • Increased risk for upper aerodigestive tract cancers (OR=1.62, 95% CI: 1.12, 2.34)

  • Decreased risk for genitourinary cancers (OR=0.73, 95% CI: 0.58, 0.92)

  • Ethnicity-dependent breast cancer risk:

    • Increased in Asian women (OR=1.91, 95% CI: 1.08, 3.40)

    • Not significant in Caucasian women (OR=0.92, 95% CI: 0.71, 1.18)

• Multiple primary neoplasm (MPN) risk:

  • Patients with MPN involving tobacco-related cancers show significant association with SULT1A1*2 polymorphism (OR=5.50, 95% CI: 1.09, 27.7)

  • This suggests SULT1A1 variants may influence susceptibility to developing multiple cancers

• Mechanistic insights:

  • The dual role of SULT1A1 in both detoxification and bioactivation explains tissue-specific risk profiles

  • Interaction between genetic variants and different endogenous/exogenous carcinogens likely modulates cancer risk

• Research applications:

  • SULT1A1 antibodies can help characterize expression patterns in precancerous and cancerous tissues

  • Immunohistochemical studies can identify populations of cells with altered SULT1A1 expression

  • Correlation of SULT1A1 expression with clinical outcomes may provide prognostic information

These advances highlight the importance of considering both genetic and environmental factors when evaluating SULT1A1's role in cancer risk assessment.